Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.

ABSTRACT:

Importance

Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant.

Objective

To determine the relative effectiveness and safety of 3 common alternate treatments for MDD.

Design, setting, and participants

From December 2012 to May 2015, 1522 patients at 35 US Veterans Health Administration medical centers who were diagnosed with nonpsychotic MDD, unresponsive to at least 1 antidepressant course meeting minimal standards for treatment dose and duration, participated in the study. Patients were randomly assigned (1:1:1) to 1 of 3 treatments and evaluated for up to 36 weeks.

Interventions

Switch to a different antidepressant, bupropion (switch group, n = 511); augment current treatment with bupropion (

SUBMITTER: Mohamed S 

PROVIDER: S-EPMC5817471 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature